Nanobiotix (NASDAQ:NBTX) — Market Cap & Net Worth
Market Cap & Net Worth: Nanobiotix (NBTX)
Nanobiotix (NASDAQ:NBTX) has a market capitalization of $1.14 Billion ($1.14 Billion) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8553 globally and #2324 in its home market, demonstrating a 4.18% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nanobiotix's stock price $35.12 by its total outstanding shares 48387950 (48.39 Million). Analyse NBTX operating cash flow to see how efficiently the company converts income to cash.
Nanobiotix Market Cap History: 2020 to 2026
Nanobiotix's market capitalization history from 2020 to 2026. Data shows growth from $798.40 Million to $1.70 Billion (14.44% CAGR).
Index Memberships
Nanobiotix is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.05% | #228 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #881 of 3165 |
Weight: Nanobiotix's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Nanobiotix Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nanobiotix's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
-11.96x
Nanobiotix's market cap is -11.96 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $798.40 Million | $50.00K | -$33.62 Million | 15968.02x | N/A |
| 2021 | $391.94 Million | $2.65 Million | -$47.00 Million | 148.07x | N/A |
| 2022 | $177.58 Million | $4.78 Million | -$57.04 Million | 37.18x | N/A |
| 2023 | $352.26 Million | $36.21 Million | -$39.70 Million | 9.73x | N/A |
| 2024 | $138.87 Million | $-11.61 Million | -$68.13 Million | -11.96x | N/A |
Competitor Companies of NBTX by Market Capitalization
Companies near Nanobiotix in the global market cap rankings as of May 4, 2026.
Key companies related to Nanobiotix by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Nanobiotix Historical Marketcap From 2020 to 2026
Between 2020 and today, Nanobiotix's market cap moved from $798.40 Million to $ 1.70 Billion, with a yearly change of 14.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.70 Billion | +51.90% |
| 2025 | $1.12 Billion | +705.57% |
| 2024 | $138.87 Million | -60.58% |
| 2023 | $352.26 Million | +98.37% |
| 2022 | $177.58 Million | -54.69% |
| 2021 | $391.94 Million | -50.91% |
| 2020 | $798.40 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Nanobiotix was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.14 Billion USD |
| MoneyControl | $1.14 Billion USD |
| MarketWatch | $1.14 Billion USD |
| marketcap.company | $1.14 Billion USD |
| Reuters | $1.14 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nanobiotix
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esop… Read more